| De innovatione: The concept of innovation for medical technologies and its implications for healthcare policy-making O Ciani, P Armeni, PR Boscolo, M Cavazza, C Jommi, R Tarricone Health Policy and Technology 5 (1), 47-64, 2016 | 84 | 2016 |
| Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe M Cavazza, Y Kodra, P Armeni, M De Santis, J López-Bastida, ... The European Journal of Health Economics 17, 19-29, 2016 | 80 | 2016 |
| The social burden and quality of life of patients with haemophilia in Italy DT Yllka Kodra, Marianna Cavazza, Arrigo Schieppati Blood Transfusion 12 (suppl. 3), 567-575, 2014 | 74 | 2014 |
| Social/economic costs and quality of life in patients with haemophilia in Europe M Cavazza, Y Kodra, P Armeni, M De Santis, J López-Bastida, ... The European Journal of Health Economics 17, 53-65, 2016 | 73 | 2016 |
| La spesa sanitaria: composizione ed evoluzione P Armeni, F Ferré Rapporto OASI 2013, 2013 | 64* | 2013 |
| Implementation of value-based pricing for medicines C Jommi, P Armeni, F Costa, A Bertolani, M Otto Clinical therapeutics 42 (1), 15-24, 2020 | 63 | 2020 |
| The impact of HTA and procurement practices on the selection and prices of medical devices G Callea, P Armeni, M Marsilio, C Jommi, R Tarricone Social science & medicine 174, 89-95, 2017 | 62 | 2017 |
| Real-world cost effectiveness of MitraClip combined with medical therapy versus medical therapy alone in patients with moderate or severe mitral regurgitation P Armeni, PR Boscolo, R Tarricone, D Capodanno, AP Maggioni, ... International journal of cardiology 209, 153-160, 2016 | 54 | 2016 |
| La spesa sanitaria: composizione ed evoluzione CF ARMENI P. "L’aziendalizzazione della sanità in Italia”, Rapporto OASI 2015, 2016 | 53 | 2016 |
| La spesa sanitaria: composizione ed evoluzione CF AMOROSO N., ARMENI P. L’aziendalizzazione della sanità in Italia”, Rapporto OASI 2016, 2016 | 53* | 2016 |
| La spesa sanitaria: composizione ed evoluzione FF ARMENI P. “L’aziendalizzazione della sanità in Italia”, Rapporto OASI 2014, 2014 | 53* | 2014 |
| La spesa sanitaria: composizione ed evoluzione FF Patrizio Armeni Rapporto OASI 2013, 2013 | 53* | 2013 |
| La spesa sanitaria: composizione ed evoluzione P Armeni, F Ferré Rapporto OASI 2012, 2012 | 53* | 2012 |
| La spesa sanitaria: composizione ed evoluzione P Armeni Rapporto OASI 2011, 2011 | 53* | 2011 |
| La spesa sanitaria: composizione ed evoluzione P Armeni Rapporto OASI 2010, 2010 | 53* | 2010 |
| La spesa sanitaria: composizione ed evoluzione P Armeni Rapporto OASI 2009, 2009 | 53* | 2009 |
| What type of clinical evidence is needed to assess medical devices? R Tarricone, PR Boscolo, P Armeni European Respiratory Review 25 (141), 259-265, 2016 | 52 | 2016 |
| Digital twins in healthcare: is it the beginning of a new era of evidence-based medicine? a critical review P Armeni, I Polat, LM De Rossi, L Diaferia, S Meregalli, A Gatti Journal of Personalized Medicine 12 (8), 1255, 2022 | 49 | 2022 |
| A meta‐analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients C Giannini, F D'ascenzo, F Fiorelli, P Spontoni, MJ Swaans, EJ Velazquez, ... ESC Heart Failure 5 (6), 1150-1158, 2018 | 41 | 2018 |
| The invisible costs of obstructive sleep apnea (OSA): Systematic review and cost-of-illness analysis L Borsoi, P Armeni, G Donin, F Costa, L Ferini-Strambi PloS one 17 (5), e0268677, 2022 | 35 | 2022 |
Rosanna TarriconeBocconi UniversityEmail verificata su unibocconi.it
